My watch list  

Streamlining Affinity Analysis for Accelerated Biologics Development and Production

High-throughput and assay versatility for rapid development and qualification of biopharmaceuticals

Dr. Helge Schnerr

The Octet® RED96e system features additional capabilities to expand the number and types of samples that can be assayed, increasing access to data that can reduce the risk in bringing a drug candidate to market.

Measurement of long assay times per sample, for up to 12 hours of experimental run time. Here, the high reproducibility of triplicates running a full kinetic characterization of antibody-antigen interaction is demonstrated.

There are several challenges associated with generating reliable kinetic and affinity information of hits at various stages of the lead selection process. The needs and challenges change as hits progress from the lead screening to characterization, optimization and to final selection stages. Label-free Bio-Layer Interferometry (BLI) enables scientists to obtain accurate information over a large range of binding rates and affinities during drug-target interaction studies. The Octet® sytems utilizing BLI are microfluidics-free and the sample analysis is non-destructive. When using BLI assays, only molecules binding to or dissociating from the biosensor can shift the interference pattern. Unbound molecules in the solution matrix or changes in the refractive index of the surrounding medium do not affect the interference pattern. This is a unique characteristic of BLI, and extends its capability to perform kinetic measurements in crude samples useful in applications for protein-protein binding screens, quantitation, affinity, and kinetic ranking especially in early stage development. The whitepaper demonstrates the capabilities on high-affinity binders - measuring long dissociation rates (>1,5 hours). Furthermore, the user-friendly and application driven software is outlined to demonstrate the benefit for a non-experienced operator.

Facts, background information, dossiers
  • interferometry
  • biolayer interferometry
  • binding affinity
  • protein-protein interaction
  • label-free analysis
  • assays
More about Molecular Devices
  • News

    Molecular Devices and Cytena Partner collaborate in single cell printing

    Molecular Devices, LLC announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This system utilizes microfluidics-based technology and real-time image analysis to isolate single cells and provide visual documentation of monoclonality for us ... more

    Molecular devices wins patent case in Europe

    Molecular Devices, LLC announced that its European Patent No. 1802752 titled “Parallel Patch Clamp System” was upheld by the European Patent Office in its original form, following a recent Opposition Proceeding.    Molecular Devices’ patent went through Opposition Proceedings before the Opp ... more

  • Companies

    Molecular Devices (UK) Limited

    Transform your protein and cell biology research As one of the world’s leading providers of innovative analytical instruments and reagents for life science research, pharmaceutical and biotherapeutic development, we are empowering scientists to unravel the complexity of cell and prote more

    Molecular Devices, LLC

    At Molecular Devices we have one focus -- our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dee ... more

    Molecular Devices GmbH


Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE